Cover Image

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	British Journal of Clinical Pharmacology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects
by: Zi‐yi Zhou, et al.
Published: (2026)

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
by: Chandrali S. Bhattacharya, et al.
Published: (2024)

Clinical study of the pharmacokinetics and pharmacodynamics of Xininurad tablets in patients with renal impairment
by: Xiaoni Wang, et al.
Published: (2025)

Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
by: Kexu Yang, et al.
Published: (2026)

Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages
by: Cheng‐jie Ke, et al.
Published: (2025)

Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
by: C. Hu, et al.
Published: (2025)

Effect of fluconazole on the pharmacokinetics of ainuovirine in healthy adult subjects
Published: (2024)

Safety, pharmacokinetics and pharmacodynamics of NXC736, a novel sphingosine‐1‐phosphate receptor modulator
by: Woo Kyung Chung, et al.
Published: (2026)

A novel synthesised STAT3 inhibitor exerts potent anti‐tumour activity by inducing lysosome‐dependent cell death
by: Marvin Xuejun Xu, et al.
Published: (2025)

Amylin analogues as a novel perspective in anti‐obesity therapy
by: Thomas A. Lutz
Published: (2026)

Probability of pharmacokinetic/pharmacodynamic target attainment for different piperacillin/tazobactam dosing regimens in renally impaired patients in a non‐intensive care unit setting
by: Emma Dohmann, et al.
Published: (2025)

Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription
by: Patrick G. Schweickert, et al.
Published: (2025)

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
by: Jean‐Yves Gillon, et al.
Published: (2025)

Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E‐based antibody–drug conjugates
by: Hsuan‐Ping Chang, et al.
Published: (2024)

A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects
by: Yusuke Tadayasu, et al.
Published: (2024)

JAK–STAT inhibitory effect of IN‐115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine
by: Jae‐Hun Ahn, et al.
Published: (2025)

Synthesis and evaluation of a novel inhibitor for the α5‐GABA A receptor in the treatment of peripheral neuralgia: Evidence from MD simulation and in vivo studies
by: Yanming Chen, et al.
Published: (2025)

How could perampanel, a potent AMPAergic antagonist, inhibit seizures but largely spare normal neurotransmission?
by: Cho‐Ming Lee, et al.
Published: (2026)

Empty lipid nanoparticles (eLNPs) with adjuvant activity induce potent immune responses
by: De‐Kui Qiu, et al.
Published: (2026)

Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study
by: Hiromitsu Imai, et al.
Published: (2024)

Preclinical pharmacokinetics of novel long‐acting tenofovir alafenamide/bictegravir solid injectable in rats
Published: (2024)

First‐in‐human assessment of safety and pharmacokinetics of EP9001A:an anti‐nerve growth factor antibody for chronic pain treatment
by: Yue Cheng, et al.
Published: (2025)

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
by: Yuhao Wang, et al.
Published: (2025)

Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM®
by: Christian Laveille, et al.
Published: (2024)

A novel selective stabilizer of the ryanodine receptor 2 prevents stress‐induced ventricular arrhythmias without impairing cardiac function
by: Nagomi Kurebayashi, et al.
Published: (2026)

Therapeutic targeting of GSK‐3β activation by the tyrosine kinase RYK in pancreatic ductal adenocarcinoma with BJ‐2412, a novel sunitinib analogue
by: Kiran Yadav, et al.
Published: (2026)

Safety, pharmacokinetics and antiviral activity of ainuovirine as 10‐day monotherapy in treatment‐naïve adults with HIV‐1
Published: (2024)

Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer
by: Yue Zhao, et al.
Published: (2024)

Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy
by: Maike Scherf‐Clavel, et al.
Published: (2025)

Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions
by: Dave Singh, et al.
Published: (2026)

Administration mode matters for 5‐fluorouracil therapy: Physiologically based pharmacokinetic evidence for avoidance of myelotoxicity by continuous infusion but not intravenous bolus
by: Chih‐Jia Chao, et al.
Published: (2024)

Population pharmacokinetics of long‐term hydroxychloroquine therapy in patients with rheumatic diseases
by: Chunlan Yang, et al.
Published: (2024)

Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
by: Yue Wu, et al.
Published: (2024)

Clozapine and norclozapine pharmacokinetic interaction with pantoprazole
by: Orwa Albitar, et al.
Published: (2026)

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
by: Andrea Baragetti, et al.
Published: (2026)

Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
by: C. Hu, et al.
Published: (2025)

Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects
by: Zhili Jin, et al.
Published: (2026)

Physiologically based pharmacokinetic modelling of cefoperazone in paediatrics
by: Qiushi Wang, et al.
Published: (2024)

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
by: Irina Baltcheva, et al.
Published: (2026)

A phase 1 evaluation of inhaled oxytocin: Physiologically‐based pharmacokinetic model informed dosing of a novel heat‐stable oxytocin delivery system
by: Pete Lambert, et al.
Published: (2026)